Abstract
Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.
Original language | English (US) |
---|---|
Pages (from-to) | 292-294 |
Number of pages | 3 |
Journal | NDT Plus |
Volume | 2 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2009 |
Keywords
- acute renal failure
- drug toxicity
- sunitinib
ASJC Scopus subject areas
- Nephrology
- Transplantation